ReviewMedical sciences (Basel, Switzerland)2023
Metaplastic Carcinoma of the Breast: Case Series of a Single Institute and Review of the Literature.
Review in Medical sciences (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Beyond the Triple-Negative Label: A Case Report on Metaplastic Breast Carcinoma.Clinical case reports · 2026Article
- Metaplastic breast cancer: a clinicopathological analysis of nine cases highlighting diagnostic challenges and aggressive behavior.Frontiers in oncology · 2026Article
- The Hippo Pathway in Metaplastic Breast Carcinoma: Prognostic Significance and Therapeutic Implications.Current issues in molecular biology · 2025Article
- [Metaplastic carcinoma of the breast with heterologous mesen-chymal (neuroectodermal) differentiation: a clinicopathological analysis and literature review].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Variability in the diagnosis and reporting of metaplastic breast carcinoma: results of an international survey.Histopathology · 2025Article
- Metaplastic breast carcinoma: a rare and aggressive entity.Annals of medicine and surgery (2012) · 2025Article
- Treatment outcomes and prognostic factors in nonmetastatic metaplastic breast cancer patients: a multicenter retrospective cohort study.Acta oncologica (Stockholm, Sweden) · 2024Article
- Better Local Disease Control With Mastectomy in Metaplastic Breast Carcinoma: Findings of a Retrospective Cohort.Cureus · 2024Article
- Clinical analysis of metaplastic breast carcinoma with distant metastases: A multi‑centre experience.Oncology letters · 2024Article
- Translational Aspects in Metaplastic Breast Carcinoma.Cancers · 2024Review
- Metaplastic carcinoma of the breast containing three histological components: a case report.Frontiers in oncology · 2024Article
- Article
- Epoxy- versus Glutaraldehyde-Treated Bovine Jugular Vein Conduit for Pulmonary Valve Replacement: A Comparison of Morphological Changes in a Pig Model.Biomedicines · 2023Article
- Pulmonary tumor with osteosarcomatous and chondrosarcomatous components: The differential diagnosis.Tzu chi medical journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metaplastic carcinoma of the breast (MpBC) is a very rare and aggressive type of breast cancer. Data focusing on MpBC are limited. The aim of this study was to describe the clinicopathological features of MpBC and evaluate the prognosis of patients with MpBC. Eligible articles about MpBC were identified by searching CASES SERIES gov and the MEDLINE bibliographic database for the period of 1 January 2010 to 1 June 2021 with the keywords metaplastic breast cancer, mammary gland cancer, neoplasm, tumor, and metaplastic carcinoma. In this study, we also report 46 cases of MpBC stemming from our hospital. Survival rates, clinical behavior, and pathological characteristics were analyzed. Data from 205 patients were included for analysis. The mean age at diagnosis was 55 (14.7) years. The TNM stage at diagnosis was mostly stage II (58.5%) and most tumors were triple negative. The median overall survival was 66 (12-118) months, and the median disease-free survival was 56.8 (11-102) months. Multivariate Cox regression analysis revealed that surgical treatment was associated with decreased risk of death (hazard ratio 0.11, 95% confidence interval 0.02-0.54,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.